

Miller, Diane M. (CDC/NIOSH/EID)

From: Dimicco, Marie [DimiccoM@WCMC.com]
Sent: Tuesday, June 16, 2009 11:50 AM
To: NIOSH Docket Office (CDC)
Subject: 105a - Haz Drug Appx A Rev

Thank you for allowing further review and opportunity to comment on the proposed changes to the NIOSH Hazardous drug appendix.

Please note that Baraclude is on both the list to add and the list to remove.

Also Bendamustine (Treanda) Alkylating agent Pregnancy Category D does not appear on the list either list. This agent was approved for use in the US in 2008.

Marie G. DiMicco, RPh, MS, PharmD
Clinical Pharmacy Manager, Oncology
Westchester Medical Center
Valhalla, NY 10595
Telephone: 914-493-1419
Fax: 914-493-1173

Pager: 914-551-0108

Email: dimiccom@wcmc.com

The information contained in this electronic e-mail transmission and any attachments are intended only for the use of the individual or entity to whom or to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, or the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any dissemination, distribution, copying or disclosure of this communication and any attachment is strictly prohibited. If you have received this transmission in error, please notify the sender immediately by telephone and electronic mail, and delete the original communication and any attachment from any computer, server or other electronic recording or storage device or medium. Receipt by anyone other than the intended recipient is not a waiver of any attorney-client, physician-patient or other privilege. Thank you